[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rectal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rectal-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,238,0,25,[9,51,78,99,124,157,185,207,233,258,280,315,339,364,383,404,427,461,484,508,534,569,601,623,645],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100652922","multicenter-retrospective-and-prospective-analysis-of-patients-with-localized-non-metastatic-rectal-cancer-in-austria-100652922",false,"NCT07780305","Multicenter Retrospective and Prospective Analysis of Patients With Localized, Non-metastatic Rectal Cancer in Austria","ABCSG R07 Rectal Cancer Registry (RCR) - Multicenter Retrospective and Prospective Analysis of Patients With Localized, Non-metastatic Rectal Cancer in Austria","ABCSG R07 RCR","Inclusion Criteria:\n\n* Female and male participants with age \\>= 18 years\n* Signed informed consent obtained prior to registration of the participant.\n* Localized rectal cancer treated with TNT or localized, non-metastatic dMMR\u002FMSI-H rectal cancer, irrespective of treatment\n\nExclusion Criteria:\n\n* Distant metastases at primary diagnosis","ALL","18 Years",{"count":21,"type":22},600,"ESTIMATED","3 Years","OBSERVATIONAL","In Austria, patients with rectal cancer that has not spread to other parts of the body are typically treated with either total neoadjuvant therapy (TNT) or immunotherapy, depending on their microsatellite status (DNA repair capacity).\n\nHowever, treatment can vary considerably between hospitals in Austria. These differences may include the type and duration of treatment, as well as the active ingredients used. There are currently no clear recommendations on which exact treatment is best for each specific case.\n\nThe aim of this observational study is to collect information on the different treatments used in Austria for patients with localized rectal cancer and to document the outcomes of these treatments.\n\nOnly information and samples collected as part of the patients' routine care will be used for the study. Participation in the study will not change or affect the treatment chosen by the treating physician.",[27,28],"Rectal Cancer","Adenocarcinoma of Rectum",[30,31,32,33,34,35,36,37],"Rectal","cancer","registry","total neoadjuvant therapy","mismatch repair-deficient","locally advanced rectal cancer","Non-interventional study","adenocarcinoma","NOT_YET_RECRUITING","2026-08-19",{"date":41,"type":42},"2026-08-21","ACTUAL",{"date":44,"type":22},"2026-09-01",{"date":46,"type":22},"2033-02-01",{"name":48,"class":49},"Austrian Breast & Colorectal Cancer Study Group","NETWORK",3,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":50},"100458800","phase-2-trial-of-the-efficacy-and-safety-of-short-and-long-course-radiation-therapy-withwithout-bmx-001-100458800","NCT05254327","Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With\u002FWithout BMX-001","A Randomized Phase 2 Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With and Without BMX-001 as Part of Total Neoadjuvant Therapy in Patients With Newly Diagnosed Locally Advanced Rectal Adenocarcinoma","Inclusion Criteria:\n\n1. Patients with pathologically confirmed locally advanced rectal adenocarcinoma who will be receiving total neoadjuvant therapy regimen with curative intent.\n2. AJCC stage II to III rectal adenocarcinoma that will require total neoadjuvant therapy.\n3. Adult, age \\> or equal to 18 years (for Nebraska, age of consent is ≥19 years old)\n4. ECOG Performance Status 0-2\n5. Hemoglobin ≥ 9.0 g\u002Fdl, ANC ≥ 1,500 \u002Fdl, platelets ≥ 100,000 \u002Fdl (The use of transfusion or other intervention to achieve Hgb \\> 9.0 g\u002Fdl is acceptable)\n6. Serum SGOT and bilirubin ≤ 1.5 times upper limit of normal\n7. Adequate renal function defined as follows:\n\n1)Serum creatinine \\\u003C 1.5 mg\u002Fdl within 2 weeks prior to enrollment or 2)Creatinine clearance (CC) ≥ 50 ml\u002Fmin within 2 weeks prior to enrollment determined by 24-hour collection or estimated by Cockcroft-Gault formula: CCr male = \\[(140 - age) x (wt in kg)\\]\u002F\\[(Serum Cr mg\u002Fdl) x (72)\\], CCr female = 0.85 x (CrCl male) 8. Signed, written informed consent prior to completing any study specific procedures 9. Negative pregnancy test for women of child-bearing potential at the time of screening 10. Women of childbearing potential and male participants must agree to use two forms of a medically effective means of birth control throughout their participation in the treatment phase of the study and until 12 months following the last study treatment 11. Chest\u002FAbdominal\u002FPelvic (CAP) CT\u002F pelvic MRI done within 8 weeks prior to randomization.\n\nExclusion Criteria:\n\n1. Breast-feeding or pregnant\n2. Active infection requiring IV antibiotics 7 days before enrollment\n3. Prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ, basal cell or carcinoma of the skin, invasive cancers with a 5-year disease-free interval, resected cancer of the bladder or low-grade (Gleason 6 or less) prostate cancer\n4. Prior history of rectal adenocarcinoma (RAC)\n5. Prior history of pelvic radiotherapy for any other type of malignancy\n6. Known hypersensitivity or contraindication to any agent in FOLFOX or CAPOX regimen.\n7. Because corticosteroids are anti-inflammatory and could interrupt oxidative stress, patients will be excluded unless they are on stable or decreasing corticosteroids dose at the time of randomization.\n\n   BMX-001 Specific Exclusion Criteria (Subjects meeting any of the following criteria are ineligible for study entry)\n8. Inadequately controlled hypertension (defined as systolic blood pressure \\>150 mmHg and\u002For diastolic blood pressure \\> 100 mmHg)\n9. Active or history of postural hypotension and autonomic dysfunction within the past year\n10. Known hypersensitivity to BMX-001\n11. Clinically significant (i.e. active) cardiovascular disease or cerebrovascular disease, for example cerebrovascular accidents ≤ 6 months prior to study enrollment, myocardial infarction ≤ 6 months prior to study enrollment, unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment\n12. History or evidence upon physical\u002Fneurological examination of central nervous system disease (e.g. seizures) unrelated to cancer unless adequately controlled by medication or potentially interfering with protocol treatment\n13. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to start of study treatment\n14. A marked baseline prolongation of QT\u002FQTc interval (e.g., repeated demonstration of a QTc interval \\>450 milliseconds (ms) (CTCAE grade 1) using the specific\u002Fusual choice by clinical center for correction factor.\n15. A history of additional risk factors for Torsades de Pointes (TdP) (e.g., congestive heart failure, hypokalemia, known family history of Long QT Syndrome).\n\nNote: Inclusion of Women and Minorities Both men and women and members of all races and ethnic groups are eligible for this trial.",{"count":59,"type":22},118,"INTERVENTIONAL",[62],"PHASE2","In this Phase 2 study, we will conduct an efficacy and safety study of the combination of investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in newly diagnosed rectal adenocarcinoma (RAC) patients.",[27],[66],"Radiation","RECRUITING","2026-08-18",{"date":70,"type":42},"2026-08-20",{"date":72,"type":42},"2022-08-15",{"date":74,"type":22},"2029-06",{"name":76,"class":77},"University of Nebraska","OTHER",{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":60,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100652378","phase-2-radiotherapy-combined-with-capeox-chemotherapy-sintilimab-and-suvemcitug-in-locally-advanced-pmmr-rectal-cancera-prospective-clinical-trial-100652378","NCT07774754","Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical Trial","RADIANT","Inclusion Criteria:\n\n* 1\\) Aged 18-75 years;\n\n  2\\) ECOG 0-1;\n\n  3\\) Histologically confirmed rectal adenocarcinoma;\n\n  4\\) Preoperative staging: cT3-4N0M0 or cT1-4N+M0;\n\n  5\\) Distance from the tumour's inferior margin to the anus ≤ 12 cm;\n\n  6\\) Tumour biopsy immunohistochemistry indicates pMMR, i.e. positive expression of all MSH1\u002FMSH2\u002FMSH6\u002FPMS2, and molecular testing indicates MSS (microsatellite-stable).\n\n  7\\) Haematological parameters: WBC \\> 4,000\u002Fmm³; PLT \\> 100,000\u002Fmm³; Hb should, in principle, be \\> 10 g\u002FdL; chronic anaemia (haemoglobin \\\u003C 10.0 g\u002FdL) is not an exclusion criterion and may be assessed by a multidisciplinary team;\n\n  8\\) Liver function: Serum total bilirubin ≤ 1.5 × ULN (for subjects with Gilbert's syndrome, total bilirubin ≤ 3 × ULN is allowed)；aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN；\n\n  9\\) Renal function: serum creatinine ≤ 1.5 × ULN, or creatinine clearance \\> 50 mL\u002Fmin;\n\n  10\\) Other: not pregnant or breastfeeding; no other malignant diseases within the past 5 years or concurrently (excluding basal cell carcinoma of the skin or cervical carcinoma in situ); no mental illness preventing the provision of informed consent; no concomitant serious diseases that would shorten survival;\n\n  11\\) No previous surgery, chemotherapy or radiotherapy for rectal cancer;\n\n  12\\) No previous immunotherapy;\n\n  13\\) Previous endocrine therapy: no restrictions.\n\nExclusion Criteria:\n\n* 1\\) Failure to sign an informed consent form;\n\n  2\\) Immunohistochemistry of tumor biopsy specimens indicating dMMR or microsatellite instability testing indicating MSI-H;\n\n  3\\) Preoperative evidence of distant metastasis;\n\n  4\\) History of severe bleeding tendency or coagulation disorders; patients who have previously or currently require long-term anticoagulant therapy (e.g., patients with atrial fibrillation who have a CHADS2 score of ≥2).\n\n  5\\) History of myocarditis, cardiomyopathy, or malignant arrhythmias. History of unstable angina, congestive heart failure, or vascular disease (e.g., an aortic aneurysm requiring surgical repair or peripheral venous thrombosis) requiring hospitalization within 12 months prior to study treatment, or other cardiac conditions that may affect the safety evaluation of the study drug (e.g., poorly controlled arrhythmias, myocardial infarction, or ischemia) ;\n\n  6\\) History of esophageal or fundic varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months prior to study treatment;\n\n  7\\) History of any arterial thromboembolic event, venous thromboembolism of Grade 3 or higher according to NCI CTCAE Version 5.0, transient ischemic attack, cerebrovascular accident, hypertensive crisis, or hypertensive encephalopathy within 6 months prior to study treatment;\n\n  8)An acute exacerbation of chronic obstructive pulmonary disease (COPD) within 1 month prior to study treatment; current hypertension with a systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg despite treatment with oral antihypertensive medications; severe hypertension that is poorly controlled with medication;\n\n  9\\) History of HIV infection or active chronic hepatitis B or C, or other active, clinically significant infections;\n\n  10\\) Subjects with active pulmonary tuberculosis (TB) who are currently receiving antituberculosis therapy or who have received such therapy within 1 year prior to screening;\n\n  11\\) Cachexia, organ dysfunction;\n\n  12\\) History of pelvic or abdominal radiation therapy;\n\n  13\\) Multiple primary colorectal cancers;\n\n  14\\) Patients with seizures requiring treatment (e.g., with steroids or antiepileptic therapy);\n\n  15\\) History of other malignancies within the past 5 years, excluding cured cervical carcinoma in situ or basal cell carcinoma of the skin;\n\n  16\\) Substance abuse, or medical, psychological, or social conditions that may interfere with the patient's participation in the study or affect the evaluation of study results;\n\n  17\\) Known or suspected allergy to the study drug or to any medication administered in connection with this trial;\n\n  18\\) Any unstable condition or situation that may jeopardize the patient's safety or compliance;Pregnant or breastfeeding women of childbearing potential who are not using adequate contraception.","75 Years",{"count":87,"type":22},18,[62],"This study is a prospective, single-arm clinical trial with a dose-reduction design, which is expected to enrol 18 patients with locally advanced rectal cancer with pMMR status. The aim is to investigate the safety and efficacy of neoadjuvant chemoradiotherapy combined with sintilimab and suvecitib.\n\nPatients will receive long-course chemoradiotherapy (concurrent capecitabine, 1000 mg\u002Fm², twice daily, days 1-14, Q3W, 2 cycles; sintilimab, 200 mg, d1, IV drip, Q3W, 2 cycles), followed by 6 cycles of the Capeox regimen in combination with sintilimab and suvecitib, namely oxaliplatin 130 mg\u002Fm², d1, IV infusion, every 3 weeks; and capecitabine 1,000 mg\u002Fm², twice daily, days 1-14, every 3 weeks; sintilimab, 200 mg, Day 1, IV drip, every 3 weeks; suvectitumab (anti-angiogenic agent), 2.0\u002F1.5\u002F1.0 mg\u002Fkg, Day 1, IV drip, every 3 weeks. A total of 8 cycles of sintilimab and 6 cycles of suvectitumab were administered during the neoadjuvant treatment period.\n\nIf, following completion of neoadjuvant therapy, the subject has not achieved cCR\u002Fnear-cCR status, TME surgery or other therapeutic surgery shall be performed; the interval between the final dose of suvectitumab and surgery should be ≥6 weeks. If cCR\u002Fnear-cCR status is achieved, watchful waiting or other treatment options shall be discussed with the patient. The adjuvant treatment regimen following surgery shall be determined by the investigator based on the patient's pathological results.",[27],"2026-08-17",{"date":39,"type":42},{"date":44,"type":22},{"date":95,"type":22},"2031-09-01",{"name":97,"class":77},"Sun Yat-sen University",1,{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":106,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":116,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100329789","biomarkers-for-predicting-neoadjuvant-chemoradio-resistance-for-middle-low-advanced-rectal-cancer-100329789","NCT03573791","Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer","Identification of Tissue Biomarkers for Predicting Neoadjuvant Chemoradio-resistance in Patients With Middle-low Local Advanced Rectal Cancer.","Inclusion Criteria:\n\n* Histopathology proved to be adenocarcinoma of the rectum.\n* The edge of tumor is within 12cm of anus margin.\n* According to the eighth edition of AJCC TNM staging standard ,that staging for Ⅱ-Ⅲ period, as T3-T4, N0 or any T, N1-2.\n* There is no history of chemotherapy, radiotherapy or immunotherapy before neoadjuvant therapy.\n* Understand and agree to sign the informed consent for the study.\n\nExclusion Criteria:\n\n* With intestinal obstruction or impending obstruction, or perforation.\n* With other malignancies occurred within 5 years.",{"count":107,"type":22},152,"Neoadjuvant therapy has been widely applied to locally advanced rectal cancer. However, about 50% of patients receiving this therapy do not respond well as evidenced by the fact that their T or N stages are not effectively decreased judged by postoperative pathological examination. The purpose of this trail is to identify the biomarkers (from within patients' tumor mass before neoadjuvant therapy) to predict resistance to neoadjuvant therapy. These biomarkers can help stratify neoadjuvant-resistant patients towards surgery while avoiding unnecessary chemoradio-based neoadjuvant therapy.",[27,110,111,112,113,114,115],"Cancer of Rectum","Cancer of the Rectum","Neoplasms, Rectal","Rectal Tumors","Rectum Cancer","Rectum Neoplasms",{"date":68,"type":42},{"date":118,"type":42},"2018-05-21",{"date":120,"type":22},"2028-05-21",{"name":122,"class":77},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",2,{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":60,"phases":134,"briefSummary":136,"conditions":137,"keywords":142,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":98},"100300428","phase-1-administering-peripheral-blood-lymphocytes-transduced-with-a-murine-t-cell-receptor-recognizing-the-g12v-variant-of-mutated-ras-in-hla-a1101-patients-100300428","NCT03190941","Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","A Phase I\u002FII Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","* INCLUSION CRITERIA:\n* Measurable (per RECIST V1.1 criteria, metastatic, or unresectable malignancy expressing G12V mutated KRAS as assessed by one of the following methods: RT-PCR on tumor tissue, tumor DNA sequencing, or any other CLIA-certified laboratory test on resected tissue. Patients shown to have tumors expressing G12V mutated NRAS and HRAS will also be eligible as these oncogenes share complete amino acid homology with G12V mutated KRAS for their first 80 N-terminal amino acids, completely encompassing the target epitope.\n* Patients must be HLA-A\\*11:01 positive as confirmed by the NIH Department of Transfusion Medicine.\n* Confirmation of the diagnosis of cancer by the NCI Laboratory of Pathology.\n* Patients must have:\n\n  * previously received standard systemic therapy for their advanced cancer and have been either non-responders or have recurred, specifically:\n\n    * Patients with metastatic colorectal cancer must have had at least two systemic chemotherapy regimens that include 5FU, leucovorin, bevacizumab, oxaliplatin, and irinotecan (or similar agents), or have contraindications to receiving those medications.\n    * Patients with pancreatic cancer must have received gemcitabine, 5FU, and oxaliplatin (or similar agents), or have contraindications to receiving those medications.\n    * Patients with non-small cell lung cancer (NSCLC) must have had appropriate targeted therapy as indicated by abnormalities in ALK, EGFR, or expression of PDL- 1. Other patients must have had platinum-based chemotherapy.\n    * Patients with ovarian cancer or prostate cancer must have had approved first-line chemotherapy.\n\nOR\n\n* declined standard treatment\n* Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for one month after treatment for the patient to be eligible. Patients\n\nwith surgically resected brain metastases are eligible.\n\n* Age greater than or equal to 18 years and less than or equal to 72 years.\n* Clinical performance status of ECOG 0 or 1\n* Patients must be willing to practice birth control from the time of enrollment on this study and 12 months after the last dose of combined chemotherapy for women and for 4 months after treatment for men.\n* Women of child-bearing potential must be willing to undergo pregnancy testing prior to the start of treatment because of the potentially dangerous effects of the treatment on the fetus.\n\nNOTE: Certain malignancies may secrete hormones that produce false positive pregnancy tests. Serial blood testing (e.g. HCG measurements) and\u002F or ultrasound may be performed for clarification.\n\n* Serology\n\n  * Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive may have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities.)\n  * Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.\n* Hematology\n\n  * ANC greater than 1000\u002Fmm\\^3 without the support of filgrastim\n  * WBC greater than or equal to 2500\u002Fmm\\^3\n  * Platelet count greater than or equal to 80,000\u002Fmm\\^3\n  * Hemoglobin \\> 8.0 g\u002FdL. Subjects may be transfused to reach this cut-off.\n* Chemistry\n\n  * Serum ALT\u002FAST less than or equal to 5.0 times ULN\n  * Total bilirubin less than or equal to 2.0 mg\u002FdL, except in patients with Gilbert s Syndrome, who must have a total bilirubin less than 3.0 mg\u002FdL.\n* Patients must have either an eGFR \\> 60 mL\u002Fm (based on serum creatinine and lab nomogram) or a formal 6-24h CrCl \\> 60 mL\u002Fm.\n* Patients must have completed any prior systemic therapy at the time of enrollment.\n\nNote: Patients may have undergone minor surgical procedures or limited field radiotherapy within the four weeks prior to enrollment, as long as related major organ toxicities have recovered to less than or equal to grade 1.\n\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n* Willing to sign a durable power of attorney.\n* Subjects must be co-enrolled on protocol 03C0277.\n\nEXCLUSION CRITERIA:\n\n* Large volume pulmonary irradiation.\n* Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant.\n* Concurrent systemic steroid therapy.\n* Active systemic infections requiring anti-infective treatment, coagulation disorders, or any other active or uncompensated major medical illnesses.\n* Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).\n* Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune-competence may be less responsive to the experimental treatment and more susceptible to its toxicities.)\n* History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or aldesleukin.\n* History of coronary revascularization or ischemic symptoms\n* For select patients with a clinical history prompting cardiac evaluation: last known LVEF less than or equal to 45%.\n* For select patients with a clinical history prompting pulmonary evaluation: known FEV1 less than or equal to 50% or DLCO less than 60%.\n* Patients who are receiving any other investigational agents.","72 Years",{"count":133,"type":22},110,[135,62],"PHASE1","Background:\n\nA new cancer therapy involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person. This therapy is called gene transfer using anti-KRAS G12V mTCR cells.\n\nObjective:\n\nTo see if anti-KRAS G12 V mTCR cells are safe and can shrink tumors.\n\nEligibility:\n\nAdults at least 18 years old with cancer that has the KRAS G12V molecule on the surface of tumors.\n\nDesign:\n\nIn another protocol, participants will:\n\nBe screened\n\nHave cells harvested and grown\n\nHave leukapheresis\n\nIn this protocol, participants will have the procedures below.\n\nParticipants will be admitted to the hospital.\n\nOver 5 days, participants will get 2 chemotherapy medicines as an infusion via catheter in the upper chest.\n\nA few days later, participants will get the anti-KRAS G12V mTCR cells via catheter.\n\nFor up to 3 days, participants will get a drug to make the cells active.\n\nA day after getting the cells, participants will get a drug to increase their white blood cell count. This will be a shot or injection under the skin.\n\nParticipants will recover in the hospital for 1-2 weeks. They will have lab and blood tests.\n\nParticipants will take an antibiotic for at least 6 months.\n\nParticipants will have visits every few months for 2 years, and then as determined by their doctor.\n\nVisits will be 1-2 days. They will include lab tests, imaging studies, and physical exam. Some visits may include leukapheresis or blood drawn.\n\nParticipants will have blood collected over several years.\n\n...",[138,139,140,141,27],"Pancreatic Cancer","Gastric Cancer","Gastrointestinal Cancer","Colon Cancer",[143,144,145,146,147],"KRAS","HRAS","NRAS","Cell Therapy","Immunotherapy","2026-08-15",{"date":68,"type":42},{"date":151,"type":42},"2017-09-21",{"date":153,"type":22},"2028-06-29",{"name":155,"class":156},"National Cancer Institute (NCI)","NIH",{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":4},"100651621","quality-of-life-of-patients-after-rectal-cancer-resection--100651621","NCT07764120","Quality of Life of Patients After Rectal Cancer Resection .","Quality of Life at 3 Years of Patients Treated by Abdominoperineal Resection or Rectal Resection and Coloanal Anastomosis for Cancer of the Lower Rectum.","QRAAP","Inclusion Criteria:\n\n* Patients over 18 years\n* Patient operated on for adenocarcinoma of the lower rectum without metastasis\n* Total mesorectal excision (TME) surgery for cancer\n* Patients who underwent coloanal anastomosis or abdominoperineal amputation, regardless of the method and approach, between January 2005 and December 2021\n* Patients' information and non-opposition\n\nExclusion Criteria:\n\n* Double localisation of colorectal cancer during surgery\n* Resection of another organ due to invasion (T4 tumours)\n* Chemotherapy for recurrence or metastasis during follow-up\n* Surgical complication of coloanal anastomosis requiring permanent stoma",{"count":166,"type":22},22,"Surgical treatment of cancer of the lower rectum by resection and coloanal anastomosis or abdominoperineal resection in both cases exposes the patient to significant functional digestive sequelae (anal incontinence or permanent stoma), and also to urinary and sexual consequences, which have a major impact on quality of life.\n\nLocally advanced rectal cancers leading to one or the other of these two procedures have practically the same characteristics: always fairly large cancers, located in the distal third of the rectum, in most cases requiring neoadjuvant chemoradiotherapy and a temporary or permanent stoma.\n\nRecent surgical advances and improved adjuvant therapy are increasingly steering patients toward \"at all costs\" sphincter preservation, sometimes at the expense of quality of life.\n\nAbdominoperineal resection with permanent ostomy is classically believed to have a detrimental effect on quality of life compared with resection and low anastomosis. Very few studies have compared these two procedures in terms of long-term functional results and quality of life. Most of them are small and\u002For retrospective case series, involve heterogeneous populations, or use questionable methodology.\n\nAs randomized patients between sacrifice or preservation of the anus, seem not ethical, the study propose to compare in a prospective single-center study two very close populations of patients presenting advanced cancer of the lower rectum after chemoradiotherapy, treated by abdominoperineal resection or resection and coloanal anastomosis, with the objective to determine long-term quality of life.\n\nMost studies, including the recent prospective one, showed no substantial difference between the two procedures in terms of quality of life or functional difficulties. With the caveat of the biases, sphincter conservation would nevertheless seem that is associated with a better quality of life.The aim of this single-centre retrospective study is to compare the quality of life over more than three years in a population of patients with locally advanced lower rectal cancer who underwent surgery after chemoradiotherapy, either rectal resection and coloanal anastomosis or abdominoperineal amputation.\n\nThis study might conclude that one procedure is superior to the other in terms of quality of life and help to choose the best technique, which could lead to substantial changes in the management of advanced cancers of the lower rectum.",[27],[170,171,172,173,174,175],"Rectal cancer","abdominoperineal resection","rectal resection","coloanal anastomosis","quality of life","genitourinary disorders","2026-08-11",{"date":178,"type":42},"2026-08-13",{"date":180,"type":22},"2026-08",{"date":182,"type":22},"2026-11-30",{"name":184,"class":77},"University Hospital, Grenoble",{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":60,"phases":194,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":4},"100651330","randomized-controlled-trial-of-the-surgdiff-model-for-predicting-surgical-difficulty-to-help-choose-approach-in-mid-low-rectal-cancer-100651330","NCT07761169","Randomized Controlled Trial of the SurgDiff Model for Predicting Surgical Difficulty to Help Choose Approach in Mid-Low Rectal Cancer","Inclusion Criteria:\n\n1. Pathological examination confirmed a diagnosis of rectal adenocarcinoma; radical surgery is recommended.\n2. The inferior border of the tumor is ≥1 cm from the dentate line and ≤7 cm from the anal verge;\n3. Preoperative staging was assessed in a stage of c\u002FycT1-3N0-2M0;\n4. The cardiac, pulmonary, hepatic, renal, and other organ functions are adequate, and the patient can tolerate laparoscopic surgery.\n\nExclusion Criteria:\n\n1. Intraoperative exploration is unable to achieve R0 resection or preservation of the anus;\n2. Lateral lymph node dissection is required;\n3. Patients with a history of severe mental illness, immune disorders, or those taking hormonal medications;\n4. Any other circumstances in which the investigator deems it inappropriate for inclusion.","80 Years",{"count":193,"type":22},68,[195],"NA","This study aims to investigate the feasibility of utilizing the SurgDiff surgical difficulty prediction model to assist surgeons in formulating precise surgical plans.",[27],"2026-08-07",{"date":200,"type":42},"2026-08-12",{"date":202,"type":22},"2026-08-30",{"date":204,"type":22},"2030-09-30",{"name":206,"class":77},"Peking Union Medical College Hospital",{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":60,"phases":216,"briefSummary":217,"conditions":218,"keywords":219,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":123},"100554589","contact-radiotherapy-for-rectal-cancer-100554589","NCT06501053","Contact Radiotherapy for Rectal Cancer","Contact Radiotherapy for Rectal Cancer (CORRECT): a Multicenter Randomized Phase II Trial","CORRECT","Inclusion Criteria:\n\n* Adenocarcinoma of the rectum classified as:\n* cT1-cT3ab, \\\u003C 5 cm largest diameter and \\\u003C ½ circumference (MRI staging), N0-N1 (\\\u003C= 3 nodes \\\u003C 8mm diameter), M0\n* Performance status (ECOG) 0-1\n* Operable patient\n* Tumor accessible to endocavitary contact X-ray brachytherapy with a distance from the lower tumor border to the anal verge ≤10 cm\n* 18 years or above\n* No comorbidity preventing treatment\n* Patient having read the information note and having signed the informed consent\n* Follow-up possible\n\nExclusion Criteria:\n\n* Inoperable patient\n* T3cd, T4, T≥ 5cm, Involvement of more than half of the bowel circumference\n* Distance from the lower tumor border to the anal verge \\>10 cm\n* N2-status at diagnosis or N1 with any node\\>= 8 mm diameter\n* Patient presenting with metastasis at diagnosis (M1)\n* Previous pelvic irradiation\n* Tumor with extramural vascular invasion\n* Poorly differentiated tumor\n* Simultaneous progressive cancer\n* Tumor invading external anal sphincter or growth within 1 mm of the levator\n* Tumor within 1 mm from MRF (mesorectal fascia)\n* Patient unable to receive CXB or CRT\n* Any significant concurrent medical illness that in the opinion of the investigator would preclude protocol therapy\n* Patient with history of poor compliance or current or past psychiatric conditions or severe acute or chronic medical conditions that would interfere with the ability to comply with the study protocol\n* Concurrent enrolment in another clinical trial using an investigational anti-cancer treatment within 28 days prior to the first dose of study treatment\n* Total DPD deficiency",{"count":133,"type":22},[195],"The aim of the CORRECT phase 2 study is to show non-inferiority of Contact x-ray brachytherapy (CXB) + short-course radiotherapy (SCRT) compared to the experimental arm of the OPERA trial in organ preservation for early and early intermediate rectal cancer (cT1-3abN1).",[27],[220,221,222,223],"organ sparing","brachytherapy","radiotherapy","nonoperative","2026-08-06",{"date":226,"type":42},"2026-08-10",{"date":228,"type":42},"2025-03-03",{"date":230,"type":22},"2032-11",{"name":232,"class":77},"Alexander Valdman",{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":60,"phases":243,"briefSummary":244,"conditions":245,"keywords":246,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":251,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":257},"100402876","preoperative-short-course-radiation-therapy-with-protons-compared-to-photons-in-high-risk-rectal-cancer-prorect-100402876","NCT04525989","Preoperative Short-Course Radiation Therapy With PROtons Compared to Photons In High-Risk RECTal Cancer (PRORECT)","Preoperative Short-Course Radiation Therapy With PROtons Compared to Photons In High-Risk RECTal Cancer (PRORECT): A Prospective Randomized Swedish Phase II Trial","PRORECT","Inclusion Criteria:\n\nInclusion Criteria - Primary tumour characteristics\n\n* Biopsy-proven, newly diagnosed primary rectal adenocarcinoma, i.e. with the lowest part of the tumour less than 16 cm from the anal verge detected using a rigid rectoscope.\n* Locally advanced tumour fulfilling at least one of the following criteria on pelvic MRI indicating high risk of failing locally and\u002For systemically:\n\n  * Clinical stage (c) T4b, i.e. infiltration of an adjacent organ or structure like the prostate, urinary bladder, uterus, sacrum, pelvic floor or side-wall (according to TNM version 8).\n  * cT4a, i.e. peritoneal involvement.\n  * Extramural vascular invasion (EMVI+).\n  * N2-status regarded as metastatic according to ESGAR consensus criteria\n  * Positive MRF, i.e. tumor or lymph node one mm or less from the mesorectal fascia.\n  * Metastatic lateral nodes (lat LN+) according to ESGAR consensus criteria\n\nInclusion Criteria - General\n\n* Staging done within 6 weeks before start of radiotherapy. No contraindications to chemotherapy with CAPOX including adequate blood counts, (within 5 weeks prior to randomisation):\n\n  * white blood count ≥4.0 x 10\\*9\u002FL\n  * platelet count ≥100 x 10\\*9\u002FL\n  * clinically acceptable haemoglobin levels\n  * creatinine levels indicating renal clearance of ≥50 ml\u002Fmin\n  * bilirubin ˂35 µmol\u002Fl.\n* ECOG performance score ≤1\n* Patient is considered to be mentally and physically fit for chemotherapy with CAPOX as judged by the oncologist.\n* Age ≥18 years\n* Written informed consent.\n* Adequate potential for follow-up.\n\nExclusion Criteria:\n\n* Extensive growth into cranial part of the sacrum (above S3) or the lumbosacral nerve roots indicating that surgery will never be possible even if substantial tumour down-sizing is seen.\n* Presence of metastatic disease or recurrent rectal tumour. Familial Adenomatosis Polyposis coli (FAP), Hereditary Non-Polyposis Colorectal Cancer (HNPCC), active Crohn's disease or active ulcerative Colitis.\n* Concomitant malignancies, except for adequately treated basocellular carcinoma of the skin or in situ carcinoma of the cervix uteri. Subjects with prior malignancies must be disease-free for at least 5 years.\n* Known DPD deficiency.\n* Any contraindications to MRI (e.g. patients with pacemakers).\n* Medical or psychiatric conditions that compromise the patient's ability to give informed consent.\n* Concurrent uncontrolled medical conditions.\n* Any investigational treatment for rectal cancer within the past month.\n* Pregnancy or breast feeding.\n* Patients with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract.\n* Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac dysrhythmia, e.g. atrial fibrillation, even if controlled with medication) or myocardial infarction within the past 12 months.\n* Patients with symptoms of peripheral neuropathy.\n* Patients with pacemaker or ICD\n* Patients with bilateral hip protheses",{"count":242,"type":22},254,[195],"To investigate a potential toxicity benefit of preoperative radiation therapy with protons compared to conventional photon beam radiation therapy in patients with locally advanced rectal cancer.",[27],[247,248,249,250],"Proton therapy","Preoperative radiation","Short-course","Primary adenocarcinoma",{"date":226,"type":42},{"date":253,"type":42},"2021-04-20",{"date":255,"type":22},"2028-03",{"name":232,"class":77},9,{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":266,"targetDuration":4,"studyType":60,"phases":268,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":98},"100605453","phase-2-scrt-followed-by-ak112-in-pmmrmss-mid-low-rectal-cancer-100605453","NCT07162714","SCRT Followed by AK112 in pMMR\u002FMSS Mid-low Rectal Cancer","Short-Course Radiotherapy Followed by Ivonescimab (AK112) in pMMR\u002FMSS Mid-Low Rectal Cancer: An Exploratory Phase II Clinical Study.","STAR","Inclusion Criteria:\n\n1. Aged between 18 and 75 years old;\n2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1;\n3. Histopathologically confirmed rectal adenocarcinoma, without any prior anti - tumor treatment; The status of MMR\u002FMSI is detected by IHC\u002FPCR in pathological biopsy to clarify that the patient's classification is pMMR\u002FMSS;\n4. The lower border of the lesion is ≤ 7 cm from the anal verge as determined by fibrocolonoscopy or digital rectal examination;\n5. Baseline magnetic resonance staging is cT2 - 4 and\u002For N+, excluding any of cT4b, N2, positive mesorectal fascia (MRF+), extramural venous invasion (EMVI+), lateral lymph node metastasis, and distant metastasis (according to the 8th edition of the AJCC Cancer Staging Manual);\n6. Able to accept the treatment plan during the study period;\n7. Signed written informed consent.\n\nExclusion Criteria:\n\n1. Uncontrolled epilepsy, history of central nervous system disorders or psychiatric conditions that, in the investigator's judgment, may interfere with the ability to provide informed consent or affect compliance with oral medication.\n2. Prior immunotherapy for any indication or a history of severe hypersensitivity reactions to other monoclonal antibodies.\n3. Clinically significant active cardiac disease, including symptomatic coronary artery disease, congestive heart failure (New York Heart Association \\[NYHA\\] Class II or higher), severe arrhythmias requiring medication, or a history of myocardial infarction within the past 12 months.\n4. Immunosuppressive therapy following organ transplantation.\n5. History of other malignancies within the past 5 years (excluding adequately treated non-melanoma skin cancer or carcinoma in situ).\n6. Severe uncontrolled recurrent infections or other significant uncontrolled comorbidities.\n7. Baseline laboratory values failing to meet the following criteria:Hemoglobin ≥80 g\u002FL; Absolute neutrophil count (ANC) ≥1.5×10\\^9\u002FL; Platelets ≥100×10\\^9\u002FL; ALT\u002FAST ≤2.5×upper limit of normal (ULN); Alkaline phosphatase (ALP) ≤2.5×ULN; Total bilirubin \\\u003C1.5×ULN; Serum creatinine \\\u003C1×ULN\n8. Active gastrointestinal diseases (e.g., gastric\u002Fduodenal ulcers, ulcerative colitis), unresected tumors with active bleeding, or other conditions deemed by the investigator to pose risks of gastrointestinal bleeding or perforation.\n9. Active bleeding or bleeding predisposition.\n10. Pregnancy or lactation.\n11. Hypersensitivity to any component of the investigational drug(s).",{"count":267,"type":22},30,[62],"Primary Objectives： Evaluate the complete response rate (CR rate) and safety of short - course radiotherapy combined with ivonesimab (AK112) in patients with pMMR\u002FMSS mid - low rectal cancer.\n\nSecondary Objectives： Evaluate treatment - related toxic reactions, the quality of life, long - term prognosis (local control \\[LC\\], disease - free survival \\[DFS\\] and overall survival \\[OS\\]).\n\nPatients will :\n\nReceive Radiotherapy: Pelvic IMRT or VMAT, DT 25Gy\u002F5Fx. One week after radiotherapy, begin treatment with Ivorsimab (AK112) at a dose of 20mg\u002Fkg by intravenous drip on day 1. One cycle is 21 days, and a total of 6 cycles are to be carried out.\n\nEvaluate the curative effect after 3 cycles of treatment. Patients with progressive disease (PD) will withdraw from the study, and other treatment plans will be adjusted in a timely manner. Patients with CR\u002FPR\u002FSD will continue treatment for another 3 cycles. Conduct a comprehensive assessment after 6 cycles of treatment. Patients who achieve cCR can choose the watch - and - wait approach. For patients who do not achieve cCR, TME surgery is recommended. Decide whether to perform adjuvant chemotherapy based on the postoperative pathological findings.",[27,66,271],"AK112","2026-08-04",{"date":198,"type":42},{"date":275,"type":42},"2025-10-27",{"date":277,"type":22},"2028-12-31",{"name":279,"class":77},"Zhejiang Cancer Hospital",{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":60,"phases":289,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":87},"100597545","distance-based-exercise-to-preserve-function-and-prevent-disability-100597545","NCT07059884","Distance-Based Exercise to Preserve Function and Prevent Disability","DEFEND","Inclusion Criteria:\n\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must have histologically confirmed diagnosis of one of the following cancers: anus, bladder, breast, cervix, colon\u002Frectum, endometrium, esophagus, gallbladder, head\u002Fneck, kidney, liver, lung, ovary, pancreas, prostate, sarcoma, stomach\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must be initiating outpatient cytotoxic chemotherapy for curative intent of at least 10 weeks duration (with or without concurrent radiation, immunotherapy, or other targeted therapy). Patients must be enrolled and baseline measures collected on or before administration of their second cycle of cytotoxic therapy. Patients receiving outpatient cytotoxic chemotherapy for curative intent in the neoadjuvant or adjuvant setting are eligible. Patients receiving definitive chemoradiation for the tumors listed above, are also eligible. Regimens of immunotherapy or monoclonal antibodies ONLY are not eligible\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Age 18-64 years\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have metastatic cancer\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of severe cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot be pregnant, because this study involves remotely delivered exercise, and cannot be breast-feeding as patients must be receiving cytotoxic chemotherapy, during which breast-feeding is contraindicated\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of current alcohol, substance abuse, or dementia\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Engaged in full time gainful employment of at least 30 hours per week at the time of cancer diagnosis\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Currently no self-report of engagement in competitive sports (e.g. not training for running races, triathlons, etc.) AND no self-report of twice weekly progressive resistance exercise training for at least 3 consecutive months within the past year\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Self-reported ability to walk for 6 minutes (use of assistive devices will be allowed)\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Not participating in another weight loss, physical activity, or dietary intervention clinical trial\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Predicted 6MWT distance of 550 meters or less\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Concurrent enrollment in treatment or supportive care trials (other than those focused on weight loss or exercise) is allowed with the permission of the Alliance Executive Officer and both studies' study chairs\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Eligibility is restricted to individuals who can comprehend and read English given that participation in the study will require the ability to read intervention materials and work with a coach through telehealth sessions\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): The trial is unable to accommodate the needs of deaf or blind participants as the study relies on language and visualization of exercise through telehealth sessions\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Clinicians and research staff from enrolling sites who meet following criterion will be deemed eligible to participate as a clinical stakeholder:\n\n  \\* Providing clinical care for participating patients on this study\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Ability to speak and understand English\n\nExclusion Criteria:\n\n\\-",{"count":288,"type":22},104,[195],"This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side effects can make it difficult to work, take care of family, and do other things the patient wants to do. Preliminary research shows that exercise can help prevent some of these side effects, but it can be more difficult to start an exercise program when a patient is receiving cancer treatment. The exercise program in this study is delivered through telehealth (TH) video calls. The TH sessions are delivered by trained staff that supervise resistance exercises. The trained staff also provide guidance to the patient on completing unsupervised aerobic sessions on their own. This may be a successful way to deliver an exercise program and make it easier for cancer patients to exercise in their own home during treatment.",[292,293,294,295,296,141,297,298,299,139,300,301,302,303,304,138,305,27,306],"Localized Malignant Solid Neoplasm","Anal Cancer","Bladder (Urothelial, Transitional Cell) Cancer","Breast Cancer","Cervical Cancer","Endometrial Cancer","Esophageal Cancer","Gall Bladder Cancer","Kidney Cancer","Liver Cancer","Lung Cancer","Head and Neck Cancer","Ovarian Cancer","Prostate Cancer","Sarcoma",{"date":308,"type":42},"2026-08-05",{"date":310,"type":42},"2026-02-11",{"date":312,"type":22},"2027-08-31",{"name":314,"class":77},"Alliance for Clinical Trials in Oncology",{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":60,"phases":325,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":98},"100609027","phase-2-ctdna-informed-management-of-early-stage-rectal-cancer-100609027","NCT07209215","ctDNA-Informed Management of Early-Stage Rectal Cancer","ULtra sensiTive ctDNA-Informed Management eArly-stage recTal cancEr (ULTIMATE)","ULTIMATE","Inclusion Criteria:\n\n* Tumor tissue histologically confirming rectal adenocarcinoma that is available for Natera ctDNA assay.\n* Cohort A only: Patients appropriate for receiving TNT including chemotherapy and chemoradiation.\n* Cohort B only: TNT must have included at least 4 cycles of CAPEOX or 6 cycles of FOLFOX and at least 45 Gy in 25 fractions to the pelvis during chemoradiation.\n* Patients ≥18 years of age at time of consent.\n* Ability to understand and willingness to sign the informed consent form (ICF).\n* Ability and stated willingness to adhere to the study visit schedule and protocol procedures\u002Frequirements.\n\nExclusion Criteria:\n\n* Prior treatment for rectal cancer, except for cohort B.\n* Evidence of distant metastatic disease on staging imaging (CT chest with abdominopelvic imaging by CT or MRI) within 8 weeks of enrollment.\n* Patients on hemodialysis.\n* Any condition that in the opinion of the investigator would interfere with the participant's safety or compliance while on trial",{"count":324,"type":22},200,[62],"This is a phase 2 pragmatic study to examine the utility of ctDNA-informed treatment management for participants with early-stage rectal cancer using the Signatera Genome assay. The primary aims are to 1) assess pathologic complete response (path CR) in the ctDNA informed management arm; 2) assess pathologic complete response (path CR) in the post total neoadjuvant therapy (TNT) standard of care (SOC) surgery arm; and 3) assess disease free survival (DFS) in the ctDNA informed management arm.",[328,27,329,330],"Rectal Adenocarcinoma","Early-stage Rectal Cancer","Locally Advanced Rectal Adenocarcinoma","2026-08-03",{"date":308,"type":42},{"date":334,"type":22},"2026-10",{"date":336,"type":22},"2028-12",{"name":338,"class":77},"University of California, Davis",{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":346,"targetDuration":4,"studyType":60,"phases":348,"briefSummary":349,"conditions":350,"keywords":351,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":363},"100527375","safety-of-mid-and-low-rectal-cancer-surgery-without-dissection-of-the-no253-lymph-node-s-m-o-o-t-h-100527375","NCT06146946","Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H)","Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node, a Prospective, Multicenter, Non-inferior Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patient age between 18-75 years.\n2. Colonic biopsy pathology confirms adenocarcinoma.\n3. At initial treatment, colonoscopy and imaging diagnose the tumor's lower edge as less than or equal to 7cm from the anus.\n4. At initial treatment, imaging diagnoses the tumor T stage as less than or equal to 3.\n5. At initial treatment, imaging diagnoses no enlarged lymph nodes at the root of the inferior mesenteric artery.\n6. At initial treatment, imaging diagnoses the number of mesenteric metastatic lymph nodes as less than or equal to three.\n7. Strong willingness for surgery and signed informed consent.\n\nExclusion Criteria:\n\n1. Previous history of malignant colorectal tumors.\n2. Colonic biopsy pathology reveals mucinous adenocarcinoma or signet ring cell carcinoma.\n3. Imaging diagnosis of distant metastasis.\n4. Patients who have undergone multiple abdominal-pelvic surgeries or have extensive abdominal adhesions.\n5. Patients with complications such as intestinal obstruction, intestinal perforation, or intestinal bleeding requiring emergency surgery.\n6. Extensive lesions not amenable to R0 resection.\n7. Diagnosed with other malignancies within the past five years.\n8. ASA (American Society of Anesthesiologists) classification ≥ IV and\u002For ECOG (Eastern Cooperative Oncology Group) performance status score ≥ 2.\n9. Patients with severe liver, kidney, cardiac, pulmonary, coagulation dysfunctions, or serious underlying diseases that cannot tolerate surgery.\n10. History of severe mental illness.\n11. Pregnant or breastfeeding women.",{"count":347,"type":22},1384,[195],"The goal of this clinical trial is to learn about whether it is safe to omit dissection of the No.253 lymph nodes in mid and low rectal cancer surgery. The main question it aims to answer is that if it is possible to achieve the same long-term survival with and without the dissection of the No.253 lymph node in mid and low rectal cancer surgery. Participants will underwent laparoscopic rectal radical resection with or without the dissection of the No.253 lymph node.",[27],[170,352,353],"Lymph node dissection","No.253 lymph node","2026-07-30",{"date":356,"type":42},"2026-07-31",{"date":358,"type":42},"2023-12-01",{"date":360,"type":22},"2029-12-01",{"name":362,"class":77},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",8,{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":60,"phases":372,"briefSummary":373,"conditions":374,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":379,"leadSponsor":381,"locationsCount":98},"100638680","phase-2-combining-dcsz11-with-radiation-and-chemotherapy-as-neoadjuvant-treatment-for-pmmr-locally-advanced-rectal-cancer-100638680","NCT07580339","Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer","Combining CD93 Inhibition (DCSZ11) With Short Course Radiation and Chemotherapy as Part of Total Neoadjuvant Treatment (TNT) for High-risk Mismatch Repair Proficient (pMMR) Locally Advanced Rectal Cancer (LARC)","Inclusion Criteria:\n\n* Age ≥18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.\n* Rectal cancer (with tumor tissue present at or below the peritoneal reflection) as determined by MRI pelvis or endoscopic ultrasound.\n* Have histologically proven mismatch repair proficient (pMMR) or microsatellite stable (MSS) rectal adenocarcinoma.\n* Must not have received any prior systemic treatment or radiation.\n* Patients have the following clinical staging:\n\n  * cT4 any node status\n  * Any T stage cN2 node status\n  * Any T or N status, evidence of suspicious lateral lymph nodes \\> 10 mm in size in short axis\n  * Evidence of extramural vascular invasion on MRI pelvis\n* Absence of distant metastases on CT or MRI imaging\n* Patients must have adequate organ and marrow function defined by study-specified laboratory tests and procedures.\n* Left ventricular ejection fraction (LVEF) assessment with documented LVEF ≥ 50% by either TTE or Multigated Acquisition (MUGA) (TTE preferred) within 6 months from first study drug administration.\n* For both Women and Men, must use acceptable form of birth control while on study.\n* Ability to understand and willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Have received an investigational agent or used an investigational device within 28 days of the first dose of study drug.\n* Have expected to require any other form of systemic or localized antineoplastic therapy while on study.\n* Have had surgery within 28 days of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc.).\n* History of severe hypersensitivity reaction to any monoclonal antibody.\n* History of encephalitis, meningitis, dementia, Parkinson's or uncontrolled seizures within 1 year prior to the first dose of study drug.\n* Uncontrolled infection of HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), or Tuberculosis.\n* Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Any tissue or organ allograft, regardless of need for immunosuppression, including corneal allograft.\n* Patient has a pulse oximetry of \\\u003C92% on room air.\n* Patient is on supplemental home oxygen.\n* Has clinically significant heart disease.\n* Conditions, including alcohol or drug dependence that would affect the patient's ability to comply with study visits and procedures.\n* Patient is pregnant or breastfeeding.\n* Unwilling or unable to follow the study schedule for any reason.\n* Patient received a live vaccine within 30 days of planned start of study medication.\n* Receipt of COVID-19 vaccination within 1 week of planned start of study medication or for which the planned COVID-19 vaccinations would not be completed 1 week prior to start of study medication.",{"count":267,"type":22},[62],"The purpose of this study is to evaluate the safety and clinical activity of combining DCSZ11 with radiation and capecitabine\u002Foxaliplatin (CAPOX) for the neoadjuvant treatment of patients with mismatch repair proficient (pMMR) high risk locally advanced rectal cancer.",[27],"2026-07-27",{"date":377,"type":42},"2026-07-28",{"date":334,"type":22},{"date":380,"type":22},"2030-10",{"name":382,"class":77},"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":387,"acronym":388,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":390,"enrollmentInfo":391,"targetDuration":4,"studyType":60,"phases":393,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":50},"100441112","phase-2-a-phase-i-ii-study-to-test-the-safety-and-efficacy-of-pd1-ab122-and-adenosine-receptor-ab928-antagonists-with-chemotherapy-after-short-course-radiation-for-rectal-cancer-100441112","NCT05024097","A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.","PANTHER","Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen should be included.\n\nInclusion Criteria:\n\n* Histologically confirmed diagnosis of adenocarcinoma of the rectum\n* Age ≥ 18 years\n* ECOG performance status 0-1\n* cT3N0 or cT1-3N1 or cT4 or cN2\n* 5cm from the anal verge\n* Rectal cancer amenable to total mesorectal excision\n* No evidence of distant metastases\n* No prior pelvic radiation therapy\n* No prior chemotherapy or surgery for rectal cancer\n* No infections requiring systemic antibiotic treatment\n* Hgb \\>8.0 gm\u002FdL, PLT \\> 150,000\u002Fmm3, total bilirubin ≤ 1.5x upper limit of normal, AST ≤ upper limit of normal, ALT ≤ 3x upper limit of normal\n* Patients must read, agree to, and sign a statement of informed consent prior to participation in this study. Patients who do not read or understand English or eligible but must have the consent form bread to them in its entirety by an official translator. Informed consent for non-literate or non-English speaking patients may not be obtained by using a relative or a member of the patient's clinical team as a translator\n* Female participants or reproductive potential, defined as not surgically sterilized and between menarche and 1 year post menopause, must have a negative serum pregnancy test within 4 weeks prior to initiation of study treatment\n* Female participants of reproductive potential and male participants with female partners of reproductive potential must remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive measures from the start of study treatment until 30 days after the last dose of Etrumadenant, -120 days after the last dose of Zimberelimab, whichever is longer and duration of contraception to follow oxaliplatin should be at least 9 months after the last dose for women and 6 months after the last dose for men)\n* Women with childbearing potential who are negative for pregnancy (urine or blood) and who agree to use effective contraceptive methods. A woman of childbearing potential is defined by one who is biologically capable of becoming pregnant. Reliable contraception should be used from trial screening and must be continued throughout the study.\n* Male subjects must also agree to use effective contraception.\n\nExclusion Criteria:\n\n* Recurrent rectal cancer\n* Primary unresectable rectal cancer is defined as a primary rectal tumor which, on the basis of either physical exam or pelvic MRI, is demed to be adherent or fixed to adjacent pelvic structures (en bloc resection wll not be achieved with negative margins).\n* Involved radial margin\n* Serum creatinine level \\>1.5x the upper limit of normal\n* Patients who have received prior pelvic radiotherapy\n* QTc ≥480 msec using Fredericia's QT correction formula\n* Due to the potential risk for drug-drug interactions with etrumadenant, participants must not have had:\n\n  * Treatment with known BCRP substrates with a narrow therapeutic window, administered orally (e.g., prazosin, rosuvastatin) within 4 weeks or 5 half-lives of the drug (whichever is shorter) prior to initiation of and throughout study treatment\n  * Treatment with known P-gp substrates with a narrow therapeutic window, administered orally (e.g., digoxin) within 4 weeks or 5 half-lives of the drug (whichever is shorter) prior to initiation of study treatment\n  * Treatment with known strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, phenobarbital, and St. John's Wort) and strong CYP3A4 inhibitors (e.g., clarithromycin, grapefruit juice, itraconazole, ketoconazole, posaconazole, telithromycin, and voriconazole) within 4 weeks (for investigational drugs when half- life is unknown or not accurately determined) or 5 drug-elimination half-lives of the drug (when half-life is determined), whichever is longer, or if it is a marketed drug, then 5 drug-elimination half-lives of the drug, prior to initiation of study treatment\n  * Refer to the following for more examples of relevant substrates, inhibitors, and inducers with the potential for drug-drug interactions with Etrumadenant: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-interactions-labeling\u002Fdrug-development-and-drug- interactions-table-substrates-inhibitors-and- Inducers\n  * Patients receiving herbal and natural remedies. Concomitant use of therapies that contain cannabinoids may be permitted based on the Investigator's discretion.\n  * Sensitive substrates of BSEP, MATE1and OCT2.\n* Any gastrointestinal condition that would preclude the use of oral medications (e.g., difficulty swallowing, nausea, vomiting, or malabsorption)\n* Prior treatment with an agent targeting the adenosine pathway\n* Patients with prior allogenic stem cell or solid organ transplantation\n* Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma\u002Fatopy\n* Patients with history of idiopathic pulmonary fibrosis, pneumonitis, or interstitial lung disease\n* Patients receiving treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and antitumor necrosis factor-α agents) administered at \\>10 mg\u002Fday prednisone or equivalent within 2 weeks prior to initiation of study treatment\n* Patients who received a live vaccine within 30 days\n* Patients who are known to have dihydropyrimidine dehydrogenase (DPD) deficiency\n* Patients with peripheral neuropathy Grade ≥ 2\n* History of severe allergic reactions to chimeric or humanized antibodies or fusion proteins\n* Patients with a history of any arterial thrombitic event within the past 6 months,\n* Patients with any other concurrent medical or psychiatric condition or disease which, in the investigator's judgment would make them inappropriate candidates for entry into this study\n* Patients with a history of prior malignancy within the past 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer.\n* Patients with a history of thrombotic episodes, such as deep venous thrombosis, pulmonary embolus, MI or CVA occurring more than 6 months prior to enrollment may be considered for protocol participation, provided they are on stable doses of anticoagulant therapy. Patients who are anticoagulated for atrial fibrillation or other conditions may participate, provided they are on stable doses of anticoagulant therapy.\n* Patients receiving other anticancer or experimental therapy. No other experimental therapies (including chemotherapy, radiation, hormonal treatment, antibodiy therapy, immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, matrix metalloprotease inhibitors, thalidomide, anti-VEGF\u002FFlk-1 monoclonal antibody, or other experimental drugs) of any kind are permitted while the patient is receiving study treatment.\n* Women who are pregnant or breastfeeding. Women of childbearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and for up to four weeks after the study.","90 Years",{"count":392,"type":22},43,[62],"Enrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidation chemotherapy (weeks 3-20) with mFOLFOX x9 cycles in combination with AB928 and AB122.",[27],{"date":397,"type":42},"2026-07-29",{"date":399,"type":42},"2022-03-31",{"date":401,"type":22},"2031-12",{"name":403,"class":77},"Weill Medical College of Cornell University",{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":411,"targetDuration":4,"studyType":60,"phases":413,"briefSummary":414,"conditions":415,"keywords":416,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":98},"100370063","total-meso-rectal-excision-versus-transanal-local-excision-followed-by-radiotherapy-for-t2n0m0-distal-rectal-cancer-100370063","NCT04098471","Total Meso-rectal Excision Versus Transanal Local Excision Followed by Radiotherapy for T2N0M0 Distal Rectal Cancer","Total Mesorectal Excision Versus Transanal Endoscopic Microsurgery Followed by Radiotherapy for T2N0M0 Distal Rectal Cancer: a Multicenter Randomized Trial","Inclusion Criteria:\n\n* Age between 18 and 75 years.\n* Histologically confirmed adenocarcinoma by preoperative biopsy.\n* Tumor located within 4 cm from the anal verge, confirmed by at least one of the following methods: digital rectal examination, pelvic magnetic resonance imaging (MRI), or colonoscopy.\n* Tumor size ≤3 cm, without fixation and with preserved mobility on clinical examination.\n* Clinical stage T2 rectal cancer confirmed by preoperative high-resolution pelvic MRI.\n* No radiological evidence of suspicious lymph node metastasis or distant metastasis on preoperative contrast-enhanced computed tomography (CT) and MRI.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* History of other malignant tumors within the past 5 years.\n* Poorly differentiated adenocarcinoma, mucinous adenocarcinoma, or signet ring cell carcinoma confirmed by pathological examination.\n* Multiple primary colorectal tumors.\n* Pregnant or breastfeeding women.\n* Patients with plans for pregnancy.\n* Severe psychiatric disorders.\n* Previous treatment for rectal cancer, including radiotherapy or chemotherapy.\n* Concomitant intestinal diseases, including familial adenomatous polyposis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC), active ulcerative colitis, or Crohn's disease.\n* Poor general condition or uncontrolled serious comorbidities that may affect study participation or treatment.\n* Contraindications to laparoscopic surgery, including extensive intra-abdominal adhesions caused by previous abdominal surgery or inability to tolerate pneumoperitoneum.\n* Current participation in another clinical trial.",{"count":412,"type":22},168,[195],"A randomized controlled clinical trial to compare the short and long term outcomes of transanal endoscopic microsurgery following radiotherapy or total mesorectal excision for the treatment of Rectal Cancer",[27],[417,418],"transanal endoscopic microsurgery","T2N0M0","2026-07-25",{"date":377,"type":42},{"date":422,"type":42},"2021-10-01",{"date":424,"type":22},"2030-06-01",{"name":426,"class":77},"The First Affiliated Hospital with Nanjing Medical University",{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":434,"enrollmentInfo":435,"targetDuration":4,"studyType":60,"phases":437,"briefSummary":438,"conditions":439,"keywords":445,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":98},"100649402","aerobic-exercise-and-guided-imagery-in-low-anterior-resection-syndrome-100649402","NCT07732894","Aerobic Exercise and Guided Imagery in Low Anterior Resection Syndrome","\"The Effects of Aerobic Exercise and Guided Imagery on Low Anterior Resection Syndrome After Rectal Cancer Surgery: A Randomized Controlled Study\"","Inclusion Criteria:\n\n* Upper-Middle-Lower Rectal Cancer\n* Having undergone surgery with TMJ\n* Having a protective ileostomy and a closed stoma\n* Being tumor-free according to laboratory reports (carcinoembryonic antigen), endoscopic findings, and abdominal ultrasonography and\u002For computed tomography data\n* Having at least minor LARS scores (\"between 21\" and \"42\") according to the -LARS scoring questionnaire\n* Having the ability to perform voluntary perineal traction contractions with perineal palpation\n* Being a volunteer with informed consent\n\nExclusion Criteria:\n\n* History of incontinence or defecation disorder not related to rectal cancer\n* Having another type of surgery for rectal cancer (Hartmann procedure, abdominoperineal excision, transanal endoscopic microsurgical resection, or sigmoid resection)\n* Deterioration in general health, neurological disease and\u002For physical disability\n* BMI \\> 30 kg\u002Fm2 (obese individuals)\n* Inability to answer questions or make interventions due to mental disorder","65 Years",{"count":436,"type":22},50,[195],"Low Anterior Resection Syndrome (LARS) is a common complication after sphincter-preserving rectal cancer surgery and may negatively affect bowel function and quality of life. Although exercise has been shown to improve physical function and well-being in cancer survivors, evidence regarding its effects on LARS symptoms remains limited.\n\nThis randomized controlled, multicenter study aims to evaluate the effects of an aerobic exercise program combined with guided imagery on bowel symptoms, quality of life, physical activity level, functional capacity, and psychological well-being in patients with LARS after rectal cancer surgery. Participants will be randomly assigned to either an intervention group receiving aerobic exercise and guided imagery in addition to standard care or a control group receiving standard care alone. Outcomes will be assessed at baseline and after the intervention period using validated clinical and patient-reported outcome measures.\n\nThe findings of this study may contribute to the development of evidence-based rehabilitation strategies for improving bowel function and quality of life in patients with LARS following rectal cancer surgery.",[27,440,441,442,443,444],"Fecal Incontinence and Constipation","Aerobic Exercise","Guided Imagery Exercise","Pelvic Floor Physical Therapy","Pelvic Floor Muscle Training",[446,447,448,449,450,451,452],"rectal cancer","low anterior resection syndrome","aerobic exercise","guided imagery","pelvic floor muscle training","pelvic floor rehabilitation","pelvic floor physical therapy","2026-07-23",{"date":397,"type":42},{"date":456,"type":42},"2025-12-30",{"date":458,"type":22},"2027-05-30",{"name":460,"class":77},"Biruni University",{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":467,"targetDuration":4,"studyType":60,"phases":469,"briefSummary":470,"conditions":471,"keywords":472,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":123},"100600985","phase-2-study-on-the-efficacy-and-safety-of-neoadjuvant-radiotherapy-combined-with-tislelizumab-liposomal-irinotecan-and-capecitabine-in-the-treatment-of-pmmr-locally-advanced-rectal-adenocarcinoma-with-low-rectal-involvement-100600985","NCT07104604","Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement","Here is the updated format for the \\*\\*Eligibility Criteria\\*\\* with bullet points for each item:\n\nInclusion Criteria:\n\n* Age: 18-75 years, no gender restriction\n* ECOG score 0-1\n* Biopsy-confirmed pMMR (proficient mismatch repair) localized advanced low rectal adenocarcinoma (tumor's lower edge ≤ 10 cm from the anus)\n* Presence of the following high-risk factors: T3N+\u002FT4\u002FN2\u002FEMVI+\u002FMRF+\u002Flateral lymph node metastasis\u002Finability to undergo sphincter-preserving surgery\n* Routine chest and abdominal CT scans showing no distant metastasis\n* Bone marrow function: Neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL, platelet count (PLT) ≥ 100 × 10\\^9\u002FL, hemoglobin (Hb) ≥ 70 g\u002FL\n* Liver function: ALT, AST ≤ 2.5 × ULN (upper limit of normal); total bilirubin ≤ 1.5 × ULN; serum albumin ≥ 3 g\u002FdL\n* Kidney function: Serum creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance ≥ 60 ml\u002Fmin (calculated using the Cockcroft-Gault formula)\n* For females and patients with reproductive potential, a negative pregnancy test must be done within 72 hours before starting the treatment, and the patient must agree to avoid pregnancy during the study treatment and for 6 months after the treatment. For males with reproductive potential partners, the patient must agree to use adequate medically approved contraception during and for 90 days after the final study treatment\n* Patients must agree to receive the study's neoadjuvant chemotherapy regimen and sign an informed consent form\n\nExclusion Criteria:\n\n* Patients with a history of other malignancies within the past 5 years (except for cured and non-recurring cancers such as in situ carcinoma, basal cell carcinoma of the skin, etc.)\n* Patients with active, uncontrolled bacterial, viral, or fungal infections requiring systemic treatment, defined by persistent signs\u002Fsymptoms related to infection, which do not improve despite appropriate antibiotics, antiviral treatments, and\u002For other therapies\n* Patients with uncontrolled systemic diseases, including unstable angina, myocardial infarction, congestive heart failure, severe unstable ventricular arrhythmia, history of severe pericardial disease, or other cardiovascular diseases; uncontrolled hypertension (defined as systolic blood pressure ≥ 140 mmHg and\u002For diastolic blood pressure ≥ 90 mmHg despite appropriate antihypertensive treatment), or a history of hypertensive crisis, hypertensive encephalopathy; uncontrolled diabetes (fasting blood glucose ≥ 10 mmol\u002FL), etc.\n* Patients known to be allergic or intolerant to the treatment drugs or excipients used in this study\n* Any clinical indicators showing contraindications to chemotherapy and surgery\n* Patients using strong inhibitors or inducers of enzymes such as CYP3A4, CYP2C8, and UGT1A1\n* Pregnant or breastfeeding women, and female patients of reproductive potential who refuse to use appropriate contraceptive measures during the study\n* Patients who participated in other clinical trials within 4 weeks before enrollment\n* Patients whom the investigator deems unsuitable for participation in the study",{"count":468,"type":22},51,[62],"The goal of this clinical trial is to evaluating the efficacy and safety of radiotherapy combined with Tislelizumab, Liposomal Irinotecan, and Capecitabine in patients with locally advanced mid-lower rectal cancer with pMMR.. Patients would be included as:1. Aged between 18-75 years, with no gender restrictions; 2. Biopsy pathology confirmed as pMMR type locally advanced mid-lower rectal adenocarcinoma (tumor lower margin ≤ 10 cm from the anal verge); 3.With the following high-risk factors: T3N+\u002FT4\u002FN2\u002FEMVI+\u002FMRF+\u002Flateral lymph node metastasis\u002Finability to preserve anal function during surgery; 4. No distant metastasis observed in routine chest and abdominal CT scans.",[27],[473,446,474,222,475],"Neoadjuvant therapy","liposomal irinotecan","immunotherapy",{"date":477,"type":42},"2026-07-24",{"date":479,"type":42},"2025-10-20",{"date":481,"type":22},"2027-06-30",{"name":483,"class":77},"Affiliated Cancer Hospital of Shantou University Medical College",{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":60,"phases":494,"briefSummary":496,"conditions":497,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":507},"100531875","phase-3-neoadjuvant-chemotherapy-excision-and-observation-vs-chemoradiotherapy-for-rectal-cancer-100531875","NCT06205485","Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer","A Phase 3 Randomized Trial Of Neoadjuvant Chemotherapy, Excision And Observation Versus Chemoradiotherapy For Early Rectal Cancer","NEO-RT","Inclusion Criteria:\n\n* Histologically confirmed invasive, well-moderately differentiated rectal adenocarcinoma, mismatch repair proficient.\n* MRI stage cT1 not eligible for transanal surgery or cT2-T3ab\\*. \\* T3a: \\\u003C1mm depth invasion, T3b: 1-5mm depth of invasion.\n* cN0 stage based on pelvic MRI - including absence of radiographic evidence of mesorectal nodal metastasis, tumour deposits or extramural venous invasion (EMVI).\n* M0 stage based on no evidence of metastatic disease by CT imaging of chest, abdomen and pelvis.\n* Mid to low-lying tumour eligible for transanal excision in the opinion of the treating surgeon.\n* Medically fit to undergo radical TME surgery as per treating surgeon's decision.\n* Participant is able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaires in either English or French or Spanish.\n* Age of at least 18 years.\n* No contraindications to protocol chemotherapy.\n* Adequate normal organ and marrow function: ANC ≥ x 10\\^9\u002FL; platelet count ≥ 100 x 10\\^9\u002FL; bilirubin \\\u003C 1.5 UNL, excluding Gilbert's syndrome; Estimated creatinine clearance of ≥ 50ml\u002Fmin\n* Patient must have an ECOG performance of \\\u003C2 (or Karnofsty ≥ 60%).\n* Must be accessible for treatment and follow-up\n* Males and females of reproductive potential must have agreed to use a highly effective contraceptive method during and for 6 months after completion of chemotherapy.\n* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n\nExclusion Criteria:\n\n* Pathologic high-risk factors on diagnostic biopsy: high histologic grade (poorly differentiated), mucinous or signet ring histology.\n* Patients with visible pelvic sidewall nodes on MRI.\n* Patients with unequivocal determination of nodal disease that, in the opinion of the investigator, would prohibit protocol therapy administration.\n* Previous pelvic radiation for any reason, including brachytherapy alone.\n* Patients who have had primary lesion excised prior to enrollment. If a patient has had partial excision prior to enrollment, there must be gross residual disease endoscopically for patient to be eligible.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Prior treatment for rectal cancer.\n* Patients with known dihydropyrimidine dehydrogenase deficiency (DYPD).\n* Potential trial participants should have recovered from clinically significant adverse events of their most recent therapy\u002Fintervention prior to enrollment.\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.\n* Any contra-indications to undergo MRI imaging.\n* Presence of anterior lesions above or near peritoneal reflection rendering the patient ineligible for a transanal tumour excision.\n* T3 tumours invading or abutting the internal sphincter.",{"count":493,"type":22},250,[495],"PHASE3","This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limited surgery? If radiation therapy is not given, is quality of life better?",[27],"2026-07-13",{"date":500,"type":42},"2026-07-14",{"date":502,"type":42},"2024-06-26",{"date":504,"type":22},"2030-06-30",{"name":506,"class":49},"Canadian Cancer Trials Group",113,{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":60,"phases":516,"briefSummary":517,"conditions":518,"keywords":521,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":98},"100542267","washington-university-participant-engagement-and-cancer-genomic-sequencing-center-wu-pe-cgs-100542267","NCT06340646","Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)","Eligibility Criteria:\n\n* Patients with cholangiocarcinoma, multiple myeloma, or early onset colon or rectal cancer.\n\n  * If diagnosed with multiple myeloma, must be African-American.\n  * If diagnosed with colon or rectal cancer, must be African-American AND must be no older than 65 years old at the time of diagnosis.\n  * At least 18 years old\n  * Able to understand and willing to sign an IRB-approved written informed consent document",{"count":515,"type":22},990,[195],"The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches that direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research, and to investigate the impact of directly engaging participants in decisions regarding returning of genomic results on participants' health and satisfaction. Participants in this study will be presented with the choice of types of genomic results to receive, and the Engagement Optimization Unit (EOU) will investigate the impact of this intervention on participant knowledge, expectations of benefit, personal utility, and decisional conflict.",[519,520,141,27],"Cholangiocarcinoma","Multiple Myeloma",[522,523,519,520,524,525],"Participant engagement","Genetic testing","Colorectal cancer","Underrepresented populations","2026-07-11",{"date":500,"type":42},{"date":529,"type":42},"2022-10-18",{"date":531,"type":22},"2027-01-31",{"name":533,"class":77},"Washington University School of Medicine",{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":538,"acronym":539,"eligibilityCriteria":540,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":541,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":543,"conditions":544,"keywords":547,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":98},"100646191","scarlet---italian-prospectional-observational-multicentre-study-on-treatment-for-rectal-pt1-cancer-100646191","NCT07695519","SCARLET - Italian proSpeCtionAl obseRvationaL multicEntre Study on Treatment for recTal pT1 Cancer","SCARLET","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Good performance status (Eastern Cooperative Oncology Group \\[ECOG\\] performance status 0 or 1).\n3. Primary tumor of the distal rectum (clinical T1) amenable to local endoscopic resection using Endoscopic Submucosal Dissection (ESD) or local surgical resection using Transanal Endoscopic Microsurgery (TEM) or Transanal Minimally Invasive Surgery (TAMIS).\n4. High-risk pathological T1 rectal cancer meeting at least one of the following conditions:\n\n   i) Poorly differentiated adenocarcinoma, mucinous adenocarcinoma, or signet ring cell carcinoma.\n\n   ii) Pathological submucosal invasion greater than 1000 micrometers. iii) Positive lymphatic invasion or positive venous invasion confirmed by immunohistochemistry.\n\n   iv) Tumor budding grade 2 or 3. v) Positive lateral or vertical resection margin (tumor within 1 mm of the surgical margin) or non-assessable resection margin.\n5. No lymph node or distant metastases confirmed by computed tomography of the chest, abdomen, and pelvis (clinical N0, M0 disease).\n6. Radiotherapy or chemoradiotherapy initiated within 12 weeks after local endoscopic or surgical resection.\n7. No previous rectal resection (other than local excision) or pelvic irradiation for any malignancy.\n8. Adequate organ function as assessed by the treating physician.\n9. The treating surgeons have explained to the patient that the current standard of care is Total Mesorectal Excision (TME) with D2 lymph node dissection and the patient has declined this treatment.\n10. Candidate for adjuvant chemoradiotherapy according to routine clinical practice.\n11. Written informed consent provided.\n\nExclusion Criteria:\n\n1. Synchronous or metachronous malignancy diagnosed within the previous 5 years.\n2. Infection requiring systemic treatment.\n3. Requirement for continuous systemic treatment with corticosteroids or immunosuppressive agents.\n4. Diagnosis of a hereditary colorectal cancer syndrome, including familial adenomatous polyposis or Lynch syndrome, or diagnosis of inflammatory bowel disease, including ulcerative colitis or Crohn disease.\n5. Squamous cell carcinoma, neuroendocrine neoplasm, or mixed neuroendocrine-non-neuroendocrine neoplasm histology.",{"count":542,"type":22},196,"The purpose of this prospective, observational, multicenter study is to evaluate the impact of adjuvant radiotherapy or chemoradiotherapy on disease-free survival (DFS) in patients with pathological T1 (pT1) rectal cancer presenting with at least one high-risk histological factor, such as deep submucosal invasion, poor differentiation, tumor budding, lymphovascular invasion, or positive resection margins, after local surgical or endoscopic excision, including Endoscopic Submucosal Dissection (ESD), Transanal Minimally Invasive Surgery (TAMIS), or Transanal Endoscopic Microsurgery (TEM). The study focuses on a specific patient population that has refused standard radical surgery with Total Mesorectal Excision (TME) because of its potential impact on quality of life and postoperative morbidity. The primary objective is to assess whether organ-preserving local treatment strategies can provide an effective alternative by evaluating long-term oncologic outcomes, quality of life, and colostomy-free survival.",[27,328,545,546],"Rectal Cancer Patients","Rectal Cancer, Radiotherapy",[548,549,550,551,552,553,554,555,556,557,558,559],"pT1 Rectal Cancer","Local Excision","Transanal Minimally Invasive Surgery","TAMIS","Transanal Endoscopic Microsurgery","TEM","Endoscopic Submucosal Dissection","ESD","Adjuvant Radiotherapy","Adjuvant Chemoradiotherapy","High-Risk Factors","Organ Preservation","2026-07-08",{"date":562,"type":42},"2026-07-10",{"date":564,"type":22},"2026-09",{"date":566,"type":22},"2031-09",{"name":568,"class":77},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":18,"minAge":576,"maxAge":577,"enrollmentInfo":578,"targetDuration":4,"studyType":60,"phases":579,"briefSummary":580,"conditions":581,"keywords":584,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":600},"100376703","efficacy-and-safety-of-the-cg-100-intraluminal-bypass-device-100376703","NCT04184973","Efficacy and Safety of the CG-100 Intraluminal Bypass Device","Efficacy and Safety of the CG-100 Intraluminal Bypass Device in Colorectal and Coloanal Anastomoses: Prospective, Open Label, Randomized Trial","Inclusion Criteria:\n\n1. The patient is willing to comply with protocol-specified follow-up evaluations\n2. Patient 22-65 years of age at screening, or patient 66-70 years of age at screening with up to one cardiovascular, metabolic or pulmonary comorbidity for which medication is prescribed.\n3. Patient is diagnosed with colorectal cancer\n4. Patient is scheduled for elective either open, laparoscopic or robotic with mesorectal excision (either abdominal or transanal approach) which will require the creation of an anastomosis, maximally 10 cm from the anal verge\n5. Patients who are scheduled to receive a protective stoma under routine clinical practice during their primary planned operation.\n6. Patient is scheduled to undergo mechanical bowel preparation\n7. The patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Medical Ethics Committee (EC) or Institutional Review Board (IRB).\n\nExclusion Criteria:\n\n1. Patient has local or systemic infection at the time of intervention (e.g., peritonitis)\n2. Major surgical or interventional procedures within 45 days prior to this study or planned surgical or interventional procedures within 6 months of entry into this study (not including, placement of port for chemotherapy or ureter stent insertion).\n3. Patients with ASA classification \\> 3\n4. Albumin \\\u003C 30 g\u002Fliter\n5. Patient has a diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, ischemic bowel, carcinomatosis or extensively spread inflammatory bowel disease\n6. Patients has a diagnosis of coagulopathy, thrombocytopenia, immune suppression\n7. BMI ≥ 40\n8. Patient is going through another surgical procedure (other than ileostomy, adhesiolysis) during the surgery.\n9. The patient is currently participating in another investigational drug or device study unless pre-approved by the sponsor.\n10. Patient has been taking regular systemic\u002F steroid medication in the last 6 months.\n11. Patients is taking antimetabolites or antiplatelet agents.\n12. Patient has preexisting sphincter problems\n13. Patient has evidence of extensive local disease in the pelvis or has undergone a prior pelvic anastomosis.\n14. Patients with massive diverticulosis at the sigmoid\u002Fdescending colon (viewed on preoperative CT)\n15. Any condition or abnormality which in the opinion of the investigator may jeopardize the patient's safe participation or the quality of the data\n16. Pregnant or nursing female patients. Female patients of child-bearing potential must have a negative pregnancy test done within 7 days prior to surgical procedure per site standard test.","22 Years","70 Years",{"count":493,"type":22},[195],"A randomized trial to assess the safety and efficacy of CG-100 for reducing stoma creation rate in subjects undergoing mesorectal excision.",[27,582,583],"Rectal Tumor","Rectal\u002FAnal",[585,586,587,588,589],"anastomosis","leak","mesorectal","ileostomy","colostomy","2026-07-02",{"date":592,"type":42},"2026-07-06",{"date":594,"type":42},"2020-06-23",{"date":596,"type":22},"2026-12-31",{"name":598,"class":599},"Colospan Ltd.","INDUSTRY",10,{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":4,"eligibilityCriteria":607,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":608,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":610,"conditions":611,"keywords":613,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":621,"locationsCount":123},"100487619","ctdna-and-organ-preservationpathologic-cr-in-rectal-cancer-100487619","NCT05629442","ctDNA and Organ Preservation\u002FPathologic CR in Rectal Cancer","A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation or Pathologic Complete Response After Neoadjuvant Therapy for Rectal Cancer","Inclusion Criteria:\n\n* Participants with T3, T4, or node-positive non-metastatic rectal cancer.\n* Participants must have original tumor tissue (formalin-fixed, paraffin embedded specimens) available for analysis or be willing to undergo a baseline research biopsy.\n* Participants must be 18 years of age or older.\n* ECOG 0-2.\n* Participants must be eligible for at least 3 months of FOLFOX, FOLFIRINOX\u002FFOLFOXIRI, or CAPOX\n* Participants must be eligible for long course chemoradiation to 40-54 Gy.\n* Participants must be able to understand and willing to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants must not have any other organ cancer evident at the time of enrollment.\n* Participants may not have any other concurrent serious illness that makes participation on this study impractical or clinically inappropriate.\n* Participants must not be actively or planning to be pregnant or breastfeeding",{"count":609,"type":22},60,"This prospective observational, non-therapeutic study for patients with T3, T4, or node positive rectal cancer eligible to undergo total neoadjuvant therapy.\n\nThis research study involves the collection of data and biospecimens (blood and tissue) to see if the presence of circulating tumor DNA (genetic material) ctDNA will help monitor rectal cancer more closely and potentially detect a recurrence before routine scans, performed per standard of care\n\nC2i Genomics, a biotechnology company, and the Spier Foundation are supporting this research study by providing funding for the study.",[27,612],"Non Metastatic Rectal Cancer",[27,612],"2026-06-29",{"date":616,"type":42},"2026-07-01",{"date":618,"type":22},"2026-10-01",{"date":620,"type":22},"2030-06",{"name":622,"class":77},"Massachusetts General Hospital",{"id":624,"slug":625,"hasResults":12,"nctId":626,"briefTitle":627,"officialTitle":628,"acronym":4,"eligibilityCriteria":629,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":630,"targetDuration":4,"studyType":60,"phases":632,"briefSummary":633,"conditions":634,"keywords":635,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":637,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":644},"100411885","phase-2-total-neoadjuvant-therapy-with-mfolfox-and-short-course-radiation-in-resectable-rectal-cancer-100411885","NCT04643366","Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer","Phase 2 Study of Total Neoadjuvant mFOLFOX and Short-Course Radiotherapy in Resectable Rectal Cancer","Inclusion Criteria:\n\n* Pathologic diagnosis of adenocarcinoma of the rectum (diagnosis by tissue biopsy) within 90 days prior to registration. At least a portion of the tumor must be located below the peritoneal reflection or begin within 12 cm of the anal verge on flexible endoscopy\n* Clinically staged (AJCC 8th ed.) T3-4 N0 M0 or T any N1-2 M0 based upon the following minimum diagnostic workup:\n* Colonoscopy, unless patient presents with an obstructing lesion\n* Within 30 days before initiating MFOLFOX6 treatment:\n* History\u002Fphysical examination\n* Imaging to exclude distant metastases: either contrast-enhanced CT of the chest, abdomen, and pelvis; or whole-body PET-CT; or MRI\n* Pelvic MRI (preferred) or transrectal ultrasound (TRUS) for T staging Note: Patients may have initiated standard mFOLFOX6 treatment before study registration provided that they met the above criteria before initiating treatment and can feasibly continue to CRT according to the timeline described in Section\n* ECOG Performance Status ≤2\n* Age ≥ 18 years\n* Adequate bone marrow function defined as follows:\n* Absolute neutrophil count (ANC) ≥ 1,200 cells\u002Fmm3\n* Platelets ≥ 100,000 cells\u002Fmm3\n* Hemoglobin ≥ 8.0 g\u002FdL (Note: The use of transfusion or other intervention to achieve Hgb ≥8.0 g\u002FdL is acceptable.)\n* Adequate liver and renal function defined as follows:\n* AST and alkaline phosphatase \\\u003C 2.5 x upper limit of normal (ULN)\n* Bilirubin ≤ 2.5 ULN\n* Calculated creatinine clearance (CrCl) \\> 30 mL\u002Fmin using Cockcroft-Gault formula as calculated by the standard Cockcroft-Gault equation using age, actual weight, creatinine, and gender\n* Must be deemed a candidate for curative resection by the surgical oncologist who will be performing the operation\n* Women of childbearing potential (WCBP) must have a negative serum pregnancy test performed within 7 days prior to the start of chemotherapy.\n* WCBP and men must agree to use a medically accepted form of birth control during the treatment and for 3 months following completion of chemotherapy.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Prior RT that would result in unsafe overlap of RT fields with the planned study treatment, per the treating radiation oncologist\n* Clinically significant cardiac disease, including major cardiac dysfunction, that in the opinion of the treating medical oncologist would preclude them from receiving systemic therapy with 5-fluorouracil, leucovorin or oxaliplatin.\n* Serious (ie, ≥ grade 3) uncontrolled infection\n* Pulmonary or respiratory condition that, in the opinion of the treating medical oncologist would preclude them from receiving systemic therapy with 5-fluorouracil, leucovorin or oxaliplatin.\n* Major surgery within 28 days of study enrollment (other than diverting colostomy)\n* History of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis) requiring significant intervention (eg, hospitalization, surgery, immunosuppressive medications) that would, in the opinion of the investigator, preclude study therapy\n* Prior known allergic reaction to 5-fluorouracil, leucovorin, or oxaliplatin\n* Known dipyrimidine dehydrogenase deficiency (DPD)\n* Any evidence of distant metastases (M1)\n* Pregnant or breast feeding\n* Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements",{"count":631,"type":22},64,[62],"This is phase 2 trial of neoadjuvant therapy and short-course radiotherapy in resectable rectal cancer.",[27],[636,30],"Resectable",{"date":616,"type":42},{"date":639,"type":42},"2021-01-28",{"date":641,"type":22},"2032-01-31",{"name":643,"class":77},"Virginia Commonwealth University",4,{"id":646,"slug":647,"hasResults":12,"nctId":648,"briefTitle":649,"officialTitle":649,"acronym":650,"eligibilityCriteria":651,"healthyVolunteers":652,"sex":18,"minAge":653,"maxAge":654,"enrollmentInfo":655,"targetDuration":191,"studyType":24,"phases":4,"briefSummary":657,"conditions":658,"keywords":694,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":704,"lastUpdatePostDateStruct":705,"startDateStruct":706,"completionDateStruct":708,"leadSponsor":710,"locationsCount":711},"100210159","integrated-cancer-repository-for-cancer-research-100210159","NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals",true,"19 Years","110 Years",{"count":656,"type":22},999999,"The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[138,659,302,298,660,141,27,661,293,662,663,664,139,301,665,666,667,668,669,300,670,305,671,672,673,674,675,676,677,678,679,680,681,682,683,684,685,686,295,687,688,306,689,520,304,297,690,691,692,693],"Thyroid Cancer","Thymus Cancer","Gastrointestinal Stromal Tumors","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Bladder Cancer","Penile Cancer","Testicular Cancer","Ureter Cancer","Urethral Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Salivary Gland Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Leukemia","Melanoma","Unknown Primary Tumor","Vaginal Cancer","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[138,659,695,696,697,698,699,700,701,702,295,703,692,693],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor","2026-06-25",{"date":614,"type":42},{"date":707,"type":42},"2013-11-01",{"date":709,"type":22},"2099-12",{"name":76,"class":77},42]